Parallax Volatility Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Parallax Volatility Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-40,000	Closed	-$1.25M	–	1767
2023 Q4	$1.25M	Buy	+40,000	New	+$955K	﹤0.01%	1328
2023 Q3	–	Sell	-30,000	Closed	-$719K	–	2243
2023 Q2	$719K	Buy	30,000 +3,000	+11%	+$66.7K	﹤0.01%	1531
2023 Q1	$508K	Buy	+27,000	New	+$514K	﹤0.01%	1730
2020 Q4	–	Sell	-60,000	Closed	-$2.48M	–	2197
2020 Q3	$2.48M	Buy	+60,000	New	+$2.59M	﹤0.01%	1605
2018 Q4	–	Sell	-45,700	Closed	-$948K	–	2843
2018 Q3	$948K	Hold	45,700	–	–	﹤0.01%	1286
2018 Q2	$698K	Sell	45,700 -27,400	-37%	-$489K	﹤0.01%	1190
2018 Q1	$1.64M	Buy	+73,100	New	+$2.02M	﹤0.01%	829
2017 Q4	–	Sell	-70,000	Closed	-$2.64M	–	3886
2017 Q3	$2.64M	Buy	70,000 +7,500	+12%	+$244K	﹤0.01%	765
2017 Q2	$1.74M	Buy	+62,500	New	+$1.86M	﹤0.01%	881
2016 Q2	–	Sell	-112,500	Closed	-$3.15M	–	2444
2016 Q1	$3.15M	Buy	+112,500	New	+$2.45M	0.01%	738

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Parallax Volatility Advisers's ACAD Position: Q1 2024 in Review

Parallax Volatility Advisers sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 856 shares — an estimated $26.8K sold.

Parallax Volatility Advisers first reported a position in ACAD in Q2 2017 and held it in 9 quarters. The position peaked at $2.11M in Q3 2020. 268 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

Parallax Volatility Advisers reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Parallax Volatility Advisers sold 856 Acadia Pharmaceuticals shares in Q1 2024, an estimated $26.8K.
Parallax Volatility Advisers first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 9 quarters.
Parallax Volatility Advisers's Acadia Pharmaceuticals position peaked at $2.11M in Q3 2020.
268 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Parallax Volatility Advisers's 13F filing for Q1 2024, filed 15 May 2024.